A Randomized Open-Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab+Docetaxel to Dostarlimab+Docetaxel to Docetaxel Alone in Participants with Advanced Nonsmall Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy (Costar Lung)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Non-small Cell Lung Cancer (nsclc)
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Participant has histologically or cytologically proven advanced or metastatic NSCLC, including squamous or nonsquamous cell carcinoma. 2) Participant has received no more than 2 prior lines of therapy, which must include a platinum-based chemotherapy (eg, cisplatin, carboplatin) and an anti-PD-(L)1 antibody. 3) Participant has measurable disease, that is, presenting with at least 1 measurable lesion per RECIST v1.1 as determined by the local site Investigator/radiology assessment.

You may not be eligible for this study if the following are true:

  • 1) Participant has been previously treated with an anti-PD-(L)1 or anti-PD-L2 agent that resulted in permanent discontinuation due to an AE. 2) Participant has been previously treated with an anti-TIM-3 or anti-CTLA-4 agent or docetaxel. 3) Participant has a documented sensitizing EGFR, ALK, or ROS-1 mutation.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.